# US 2022/0033381 A1 · 3-azabicyclo[3,1,1]heptane derivative and pharmaceutical composition including same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0033381 A1
- Document ID: US20220033381A1
- Status: Published application
- Kind: A1
- Application number: 17/280,353
- Filed: 2019-09-26
- Published: 2022-02-03
- Earliest claimed: 2018-09-27
- Assignees: LG Chem, Ltd.
- Applicants: LG Chem, Ltd.
- Inventors: Sung Bae LEE; Sang Yong HONG; Suk Jun YOUN
- Web page: https://patentgrep.com/patent/US20220033381A1

## CPC

- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C07D 403/06: linked by a carbon chain containing only aliphatic carbon atoms
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a compound of Formula 1, a pharmaceutically acceptable salt or isomer thereof, a pharmaceutical composition including the same, and a use. The compound of Formula 1 according to the present invention has ketohexokinase (KHK) inhibitory activity, and is effectively used for preventing or treating metabolic disease such as diabetes, diabetic complications, obesity, nonalcoholic fatty liver disease, and fatty hepatitis.

## Claims

### Claim 1

A compound of the following Formula 1, or a pharmaceutically acceptable salt or isomer thereof:
in the Formula 1,
R1 is a C3-C7 heterocycloalkyl containing N which is unsubstituted or substituted with C1-C3 alkyl,
R2 is a C1-C3 alkyl which is unsubstituted or substituted with 1-5 halogen atoms,
R3 represents —(CH2)mCO2H,
m is an integer of 0 to 2, and
X represents N or C—CN.

### Claim 2 (depends on 1)

The compound, or the pharmaceutically acceptable salt or isomer thereof according to claim 1, wherein the compound is selected from the following group:
2-((1R,5S,6R)-3-(2-((S)-2-methylazetidine-1-yl)-6-(trifluoromethyl)pyrimidine-4-yl)-3-azabicyclo[3,1,1]heptane-6-yl)acetic acid;
2-((1R,5S,6S)-3-(2-((S)-2-methylazetidine-1-yl)-6-(trifluoromethyl)pyrimidine-4-yl)-3-azabicyclo[3,1,1]heptane-6-yl)acetic acid;
2-((1R,5S,6R)-3-(5-cyano-6-((S)-2-methylazetidine-1-yl)-4-(trifluoromethyl)pyridine-2-yl)-3-azabicyclo[3,1,1]heptane-6-yl)acetic acid;
2-((1R,5S,6S)-3-(5-cyano-6-((S)-2-methylazetidine-1-yl)-4-(trifluoromethyl)pyridine-2-yl)-3-azabicyclo[3,1,1]heptane-6-yl)acetic acid; and
2-((1R,5S,6R)-3-(5-cyano-6-(pyrrolidine-1-yl)-4-(trifluoromethyl)pyridine-2-yl)-3-azabicyclo[3,1,1]heptane-6-yl)acetic acid.

### Claim 3 (depends on 1)

The compound, or the pharmaceutically acceptable salt or isomer thereof according to claim 1, which has a ketohexokinase (KHK) inhibiting activity.

### Claim 4

(canceled)

### Claim 5 (depends on 1)

A pharmaceutical composition for inhibiting ketohexokinase (KHK), or preventing or treating metabolic disease comprising the compound, or the pharmaceutically acceptable salt or isomer thereof according to claim 1, as an active ingredient and a pharmaceutically acceptable carrier.

### Claim 6

(canceled)

### Claim 7 (depends on 5)

The pharmaceutical composition for preventing or treating metabolic disease according to claim 5, wherein the metabolic disease is diabetes, diabetic complications, obesity, nonalcoholic fatty liver disease, or fatty hepatitis.

### Claim 8 (depends on 5)

The pharmaceutical composition for preventing or treating metabolic disease according to claim 5, wherein the metabolic disease is nonalcoholic fatty liver disease.

### Claim 9

(canceled)

### Claim 10 (depends on 1)

A method for treating metabolic disease in a mammal, comprising administering to the mammal in need thereof
the compound, or the pharmaceutically acceptable salt or isomer thereof according to claim 1.

### Claim 11 (depends on 10)

The method of claim 10, wherein the metabolic disease is diabetes, diabetic complications, obesity, nonalcoholic fatty liver disease, or fatty hepatitis.

### Claim 12 (depends on 10)

The method of claim 10, wherein the metabolic disease is nonalcoholic fatty liver disease.
